In Depth 9 Oct 2018 How to Capitalize on Opportunities in Underserved Disease Areas Developing treatments for underserved diseases can be surprisingly profitable for biotechs, we asked the experts to tell us more about how best to exploit these areas. We hear a lot about cancer therapies or drugs to target heart disease in the press, but overall a lot less about treatments for more underserved areas. Often successful […] October 9, 2018 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 8 Oct 2018 Cannabinoid Drugs Company Raises $300M in Public Offering GW Pharmaceuticals, a British biotech developing cannabinoid drugs, is on a high after a successful $300M public offering on the Nasdaq Stock Market. The company announced the public offering swiftly after its lead cannabinoid drug, Epidiolex, made history by being the first cannabinoid drug to obtain approval from the FDA earlier this year. GW plans […] October 8, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2018 Oxford Biotech Launches with €26M to Target ‘Immunometabolism’ Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […] October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 8 Oct 2018 Behind the Scenes of the Spanish Biotech Industry’s Boom The Spanish biotech industry is booming, but from my conversations with industry players elsewhere in Europe, it seems the country’s biotech industry keeps being a mystery for many. I caught up with experts at the Biospain conference to draw an overview of how biotech in Spain is doing in 2018. When we talk about biotech […] October 8, 2018 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2018 Lab-Grown Antivenom Shows Potential for Curing Black Mamba Snakebite Antivenoms could one day be made in the lab instead of in animals. Researchers from the Technical University of Denmark have neutralized black mamba venom in mice with lab-grown human antibodies for the first time. Snakebite is a serious problem, causing the deaths of around 100,000 people every year, and about three times that number […] October 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 5 Oct 2018 This Biotech Sticks Bacterial Proteins Together to Fight Antibiotic Resistance This week’s biotech has its base in Leuven, Belgium. The newly-founded Aelin Therapeutics hopes to combat antibiotic resistance by doing the pharmacological equivalent of boiling an egg. Mission: To develop a new type of drugs to kill bacteria that are resistant to antibiotics. In the future, the drugs could also be used to kill pathogenic […] October 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2018 This Year’s Nobel Prizes Highlight Advances in Biotechnology Immune system brakes, optical tweezers, and enzyme evolution. Three separate subjects that span this year’s Nobel Prizes in Physiology or Medicine, Physics and Chemistry. Despite the differences in theory, however, the diverse discoveries have one thing in common: they have applications in the biotechnology industry, Labiotech’s favorite subject. Releasing the immune system’s brakes in cancer […] October 4, 2018 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2018 Algorithm Proves Better Than Humans at Controlling Blood Sugar in Type 1 Diabetes A clinical trial has shown that letting an algorithm decide the amount of insulin a person with type 1 diabetes needs can help keep blood sugar levels under control. The algorithm, being developed at the University of Cambridge, is able to predict how much insulin is needed at each point in time based on the […] October 3, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2018 Septic Shock Drug Shows Promise for Personalized Medicine Septic shock may no longer be as shocking in the future, as a Phase IIa trial brings hope for a personalized immunomodulatory treatment from the French biotech Inotrem. In sepsis, the immune system overreacts to the infection of a pathogen, causing uncontrolled inflammation throughout the body and organ failure. This can lead to septic […] October 2, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2018 Update: Forbion’s Life Science Fund Tops Goal by €90M Update: The European venture capital firm Forbion closed fundraising for it’s fourth life sciences fund at €360M, a much greater amount than the anticipated €250M. The oversubscribed fund is great news for European medical biotech companies, which will be a strong focus for the fund, and shows that there is a strong interest in the […] October 1, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2018 Cancer-Sniffing Diagnostics Company Secures €43.1M Funding Intoxication is not the only condition that we could diagnose with breathalyzers. The UK-US company Owlstone Medical has secured €43.1M funding to help commercialize its tech that ‘smells’ cancer in your breath. Owlstone’s breathalyzer kit diagnoses conditions by measuring volatile organic compounds in a person’s breath. Disease pathologies affect the types and amounts of these […] October 1, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 1 Oct 2018 Could These Innovative Flu Vaccines Prevent Deaths From Deadly Outbreaks? Despite more than a century of scientific endeavour, influenza remains one of the most deadly infectious diseases worldwide. Across Europe, many biotechs are working on novel solutions that could dramatically improve the protection rates offered by current vaccines. Some may even lead to the holy grail of influenza research – a universal flu vaccine. Each […] October 1, 2018 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email